Immune thrombocytopenia following successful treatment of cancer in children

Pediatr Blood Cancer. 2006 Mar;46(3):372-6. doi: 10.1002/pbc.20341.

Abstract

A predisposition to developing immune thrombocytopenia (ITP) has not been reported in survivors of childhood cancer. We report a case series of childhood cancer survivors who developed an isolated thrombocytopenia in the presence of a normocellular bone marrow. Five children, two with endodermal sinus tumors and three with acute lymphoblastic leukemia, developed ITP at a median of 4 years (range: 0.2-8 years) after completion of therapy. We suggest the association of ITP in survivors of childhood malignancy may not be co-incidental as chemotherapy may cause persistent immune dysfunction.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Asparaginase / administration & dosage
  • Asparaginase / adverse effects
  • Bone Marrow Cells / pathology
  • Carmustine / administration & dosage
  • Carmustine / adverse effects
  • Child, Preschool
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Daunorubicin / administration & dosage
  • Daunorubicin / adverse effects
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Humans
  • Infant
  • Male
  • Neoplasms / complications*
  • Neoplasms / drug therapy
  • Neoplasms / pathology
  • Platelet Count
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Purpura, Thrombocytopenic, Idiopathic / blood
  • Purpura, Thrombocytopenic, Idiopathic / etiology*
  • Purpura, Thrombocytopenic, Idiopathic / pathology
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Asparaginase
  • Carmustine
  • Prednisone
  • Daunorubicin

Supplementary concepts

  • CBV protocol
  • PVDA protocol